Y-mAbs Faces Delay In Pediatric Neuroblastoma With Refuse-To-File Letter

Omburtamab, for CNS metastases resulting from neuroblastoma, needs more clinical and CMC data for its rolling BLA to be reviewed. The company says timelines for lead candidate naxitamab should not be affected.